BR9610492A - Veículos e intensificadores de transcitose para liberação de droga - Google Patents

Veículos e intensificadores de transcitose para liberação de droga

Info

Publication number
BR9610492A
BR9610492A BR9610492A BR9610492A BR9610492A BR 9610492 A BR9610492 A BR 9610492A BR 9610492 A BR9610492 A BR 9610492A BR 9610492 A BR9610492 A BR 9610492A BR 9610492 A BR9610492 A BR 9610492A
Authority
BR
Brazil
Prior art keywords
intensifiers
drug release
transcytosis
vehicles
transcytosis vehicles
Prior art date
Application number
BR9610492A
Other languages
English (en)
Inventor
Asrar Bari Malik
Richard Alan Johnson
Chinnaswamy Tiruppathi
Andrew Derek Sutton
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606315.1A external-priority patent/GB9606315D0/en
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of BR9610492A publication Critical patent/BR9610492A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
BR9610492A 1995-09-21 1996-09-20 Veículos e intensificadores de transcitose para liberação de droga BR9610492A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US409795P 1995-09-21 1995-09-21
GBGB9606315.1A GB9606315D0 (en) 1996-03-26 1996-03-26 Transcytosis vehicles and enhancers for drug delivery
PCT/GB1996/002326 WO1997010850A1 (en) 1995-09-21 1996-09-20 Transcytosis vehicles and enhancers for drug delivery

Publications (1)

Publication Number Publication Date
BR9610492A true BR9610492A (pt) 1999-03-30

Family

ID=26308989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610492A BR9610492A (pt) 1995-09-21 1996-09-20 Veículos e intensificadores de transcitose para liberação de droga

Country Status (15)

Country Link
US (1) US6204054B1 (pt)
EP (1) EP0851767A1 (pt)
JP (1) JPH11512451A (pt)
KR (1) KR19990063632A (pt)
CN (1) CN1195995A (pt)
AU (1) AU717329B2 (pt)
BR (1) BR9610492A (pt)
CA (1) CA2230479A1 (pt)
CZ (1) CZ50398A3 (pt)
HU (1) HUP9900017A3 (pt)
NO (1) NO981146L (pt)
NZ (1) NZ318472A (pt)
PL (1) PL326078A1 (pt)
RU (1) RU2169010C2 (pt)
WO (1) WO1997010850A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
EP0806945B1 (en) 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6264988B1 (en) 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
GB9801070D0 (en) * 1998-01-19 1998-03-18 Andaris Ltd HIV inhibition
US7455855B2 (en) * 2000-04-03 2008-11-25 Santen Pharmaceutical Co., Ltd. Delivering substance and drug delivery system using the same
DE60140069D1 (de) * 2000-10-16 2009-11-12 Cytoguide Aps Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
US20020150626A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for delivery of nucleic acids
BR0206919A (pt) * 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
US7067494B2 (en) * 2001-06-22 2006-06-27 The University Of British Columbia Antimitotic eleuthesides
US20040254197A1 (en) * 2001-09-28 2004-12-16 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethlene glycol
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003059884A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
EP3470084A1 (en) * 2002-12-09 2019-04-17 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
KR20140027554A (ko) * 2002-12-09 2014-03-06 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
PL2256134T3 (pl) * 2003-11-13 2014-06-30 Hanmi Science Co Ltd Fragment Fc Ig do nośnika leku i sposób jego wytwarzania
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
WO2009107766A1 (ja) * 2008-02-28 2009-09-03 東レ株式会社 経鼻投与用医薬組成物
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
CA2745904C (en) * 2008-12-05 2014-07-08 Abraxis Bioscience Llc Sparc binding peptides and uses thereof
CA2777628C (en) 2009-10-16 2019-12-03 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
JP5818319B2 (ja) 2009-12-14 2015-11-18 国立大学法人北海道大学 脂質膜構造体に細胞透過能を付与および/または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
NO2616045T3 (pt) * 2010-09-15 2018-03-24
WO2014197546A1 (en) * 2013-06-04 2014-12-11 The Johns Hopkins University Therapeutic strategy via controllable transepithelial delivery of therapeutics and diagnostics
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993020834A1 (en) * 1992-04-10 1993-10-28 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents

Also Published As

Publication number Publication date
HUP9900017A2 (hu) 1999-04-28
NO981146D0 (no) 1998-03-16
PL326078A1 (en) 1998-08-17
AU717329B2 (en) 2000-03-23
JPH11512451A (ja) 1999-10-26
US6204054B1 (en) 2001-03-20
CZ50398A3 (cs) 1998-07-15
KR19990063632A (ko) 1999-07-26
EP0851767A1 (en) 1998-07-08
RU2169010C2 (ru) 2001-06-20
NO981146L (no) 1998-03-16
NZ318472A (en) 1999-10-28
HUP9900017A3 (en) 2001-08-28
AU6995796A (en) 1997-04-09
CA2230479A1 (en) 1997-03-27
MX9802286A (es) 1998-08-30
WO1997010850A1 (en) 1997-03-27
CN1195995A (zh) 1998-10-14

Similar Documents

Publication Publication Date Title
BR9610492A (pt) Veículos e intensificadores de transcitose para liberação de droga
DE59608081D1 (de) Transcorneales arzneimittelfreigabesystem
BR9610707A (pt) Disposição de segurança para veículos
GB9710699D0 (en) Gastro-retentive controlled release system
DE69805262T2 (de) Fahrzeugbremssysteme
BR9607696A (pt) Veículo de liberação anidro para ingredientes cosméticos
DE69828795D1 (de) Fahrzeugbremssystem und sein Betätigungsverfahren
DK0941042T3 (da) Uhelds- og nødsituationsvogn
DE59813475D1 (de) Bremssystem und Fahrzeug
DE69633257D1 (de) Bremse sowie Betätigungsvorrichtung hierfür
FR2735430B1 (fr) Benne et vehicule la comportant
DE69835066D1 (de) Kraftfahrzeugmultiplex - Übertragungssystem und Herstellungsverfahren
BR9608771A (pt) Eixo semi-regido para veículo
AU5630098A (en) Vehicle imaging and verification
BR9503234A (pt) Conjunto de freio de veiculo
ES1031352Y (es) Parasol perfeccionado para vehiculos automoviles.
BR9501181A (pt) Pedal para automóvel e do comprimento do mesmo
ES1030646Y (es) Dispositivo de alarma para automoviles y similares
BR9504830A (pt) Dispositivo eletromagnético para frenagem e suspensão de veículos
KR960036897U (ko) 자동차 야간 안전식별기
KR960034108U (ko) 자동차 야간 안전 식별기
KR970057978U (ko) 차량의 제동 보조장치
KR970036373U (ko) 자동차의 제동장치
FI945130A0 (fi) Parkeringssystem och -anordning
KR970036986U (ko) 자동차용 센터 멤버와 크로스멤버 연결구조

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/705 (2006.01), A61K 47/62 (2017.0